{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:48:20Z","timestamp":1762177700413},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,25]]},"DOI":"10.7759\/cureus.65357","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T15:19:36Z","timestamp":1721920776000},"source":"Crossref","is-referenced-by-count":1,"title":["Novel Pharmaceuticals and Therapeutics for Tumor Necrosis Factor-Alpha-Resistant Crohn's Disease: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Blake","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haylie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Machini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of Inflammatory Bowel Disease: Innate Immune System","volume":"24","author":"Saez A","year":"2023","unstructured":"Saez A, Herrero-Fernandez B, Gomez-Bris R, S\u00e1nchez-Martinez H, Gonzalez-Granado JM. Pathophysiology of Inflammatory Bowel Disease: Innate Immune System. Int J Mol Sci. 2023, 24:10.3390\/ijms24021526","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian SS","year":"2019","unstructured":"Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019, 12:113-22. 10.25122\/jml-2018-0075","journal-title":"J Med Life"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12703\/P7-44","article-title":"Pathogenesis of Crohn's disease","volume":"7","author":"Boyapati R","year":"2015","unstructured":"Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn's disease. F1000Prime Rep. 2015, 7:44. 10.12703\/P7-44","journal-title":"F1000Prime Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura Y","year":"2006","unstructured":"Iwakura Y, Ishigame H. The IL-23\/IL-17 axis in inflammation. J Clin Invest. 2006, 116:1218-22. 10.1172\/JCI28508","journal-title":"J Clin Invest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910273","article-title":"Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention","volume":"22","author":"Pagnini C","year":"2021","unstructured":"Pagnini C, Cominelli F. Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention. Int J Mol Sci. 2021, 22:10.3390\/ijms221910273","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000660","article-title":"Epithelial ER Stress in Crohn's Disease and Ulcerative Colitis","volume":"22","author":"Cao SS","year":"2016","unstructured":"Cao SS. Epithelial ER Stress in Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis. 2016, 22:984-93. 10.1097\/MIB.0000000000000660","journal-title":"Inflamm Bowel Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.18936","article-title":"Management of Crohn Disease: A Review","volume":"325","author":"Cushing K","year":"2021","unstructured":"Cushing K, Higgins PD. Management of Crohn Disease: A Review. JAMA. 2021, 325:69-80. 10.1001\/jama.2020.18936","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i14.2078","article-title":"Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives","volume":"29","author":"Roy S","year":"2023","unstructured":"Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol. 2023, 29:2078-100. 10.3748\/wjg.v29.i14.2078","journal-title":"World J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis","volume":"6","author":"Singh S","year":"2021","unstructured":"Singh S, Murad MH, Fumery M, et al.. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021, 6:1002-14. 10.1016\/S2468-1253(21)00312-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref10","article-title":"Upadacitinib","author":"Padda IS","year":"2024","unstructured":"Padda IS, Bhatt R, Parmar M. Upadacitinib. StatPearls. StatPearls Publishing 2024, Treasure Island, FL; 2024."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169735","article-title":"Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system","volume":"14","author":"Shu Y","year":"2023","unstructured":"Shu Y, Chen J, Ding Y, Zhang Q. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Front Immunol. 2023, 14:1169735. 10.3389\/fimmu.2023.1169735","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial","volume":"16","author":"Vermeire S","year":"2022","unstructured":"Vermeire S, D'Haens G, Baert F, et al.. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis. 2022, 16:27-38. 10.1093\/ecco-jcc\/jjab133","journal-title":"J Crohns Colitis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121903","article-title":"Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD","volume":"11","author":"Martyniak A","year":"2021","unstructured":"Martyniak A, Medy\u0144ska-Prz\u0119czek A, W\u0119drychowicz A, Skocze\u0144 S, Tomasik PJ. Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD. Biomolecules. 2021, 11:10.3390\/biom11121903","journal-title":"Biomolecules"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15598","article-title":"Fecal microbiota transplantation therapy in Crohn's disease: Systematic review","volume":"36","author":"Fehily SR","year":"2021","unstructured":"Fehily SR, Basnayake C, Wright EK, Kamm MA. Fecal microbiota transplantation therapy in Crohn's disease: Systematic review. J Gastroenterol Hepatol. 2021, 36:2672-86. 10.1111\/jgh.15598","journal-title":"J Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2021.0655","article-title":"Adverse events of fecal microbiota transplantation: a meta-analysis of high-quality studies","volume":"34","author":"Michailidis L","year":"2021","unstructured":"Michailidis L, Currier AC, Le M, Flomenhoft DR. Adverse events of fecal microbiota transplantation: a meta-analysis of high-quality studies. Ann Gastroenterol. 2021, 34:802-14. 10.20524\/aog.2021.0655","journal-title":"Ann Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158494","article-title":"Stem Cell-Based Therapies for Inflammatory Bowel Disease","volume":"23","author":"Zhang HM","year":"2022","unstructured":"Zhang HM, Yuan S, Meng H, et al.. Stem Cell-Based Therapies for Inflammatory Bowel Disease. Int J Mol Sci. 2022, 23:10.3390\/ijms23158494","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-292391","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up","volume":"116","author":"Burt RK","year":"2010","unstructured":"Burt RK, Craig RM, Milanetti F, et al.. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood. 2010, 116:6123-32. 10.1182\/blood-2010-06-292391","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/biom11010082","article-title":"Efficacy and Safety of Mesenchymal Stem\/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review","volume":"11","author":"Ko JZ","year":"2021","unstructured":"Ko JZ, Johnson S, Dave M. Efficacy and Safety of Mesenchymal Stem\/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review. Biomolecules. 2021, 11:10.3390\/biom11010082","journal-title":"Biomolecules"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02533-0","article-title":"Stem cell therapy for Crohn's disease: systematic review and meta-analysis of preclinical and clinical studies","volume":"12","author":"Wang R","year":"2021","unstructured":"Wang R, Yao Q, Chen W, et al.. Stem cell therapy for Crohn's disease: systematic review and meta-analysis of preclinical and clinical studies. Stem Cell Res Ther. 2021, 12:463. 10.1186\/s13287-021-02533-0","journal-title":"Stem Cell Res Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib Induction and Maintenance Therapy for Crohn's Disease","volume":"388","author":"Loftus EV Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP, et al.. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2023, 388:1966-80. 10.1056\/NEJMoa2212728","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante M","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, et al.. Risankizumab as maintenance therapy for moderately to severely active crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022, 399:2031-2046. 10.1016\/S0140-6736(22)00466-4","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S379446","article-title":"Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn's Disease: Patient Selection and Reported Outcomes","volume":"17","author":"Horst S","year":"2023","unstructured":"Horst S, Cross RK. Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn's Disease: Patient Selection and Reported Outcomes. Drug Des Devel Ther. 2023, 17:273-82. 10.2147\/DDDT.S379446","journal-title":"Drug Des Devel Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens G","year":"2022","unstructured":"D'Haens G, Panaccione R, Baert F, et al.. Risankizumab as induction therapy for crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022, 399:2015-2030. 10.1016\/S0140-6736(22)00467-6","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0704-z","article-title":"Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials","volume":"58","author":"Suleiman AA","year":"2019","unstructured":"Suleiman AA, Khatri A, Minocha M, Othman AA. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials. Clin Pharmacokinet. 2019, 58:375-87. 10.1007\/s40262-018-0704-z","journal-title":"Clin Pharmacokinet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00842-5","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients","volume":"59","author":"Pang Y","year":"2020","unstructured":"Pang Y, Khatri A, Suleiman AA, Othman AA. Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients. Clin Pharmacokinet. 2020, 59:311-26. 10.1007\/s40262-019-00842-5","journal-title":"Clin Pharmacokinet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0546-0","article-title":"A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab","volume":"56","author":"Rosario M","year":"2017","unstructured":"Rosario M, Dirks NL, Milch C, et al.. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. Clin Pharmacokinet. 2017, 56:1287-301. 10.1007\/s40262-017-0546-0","journal-title":"Clin Pharmacokinet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i23.2457","article-title":"Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence","volume":"24","author":"Scribano ML","year":"2018","unstructured":"Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol. 2018, 24:2457-67. 10.3748\/wjg.v24.i23.2457","journal-title":"World J Gastroenterol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ085","article-title":"Risk and safety of probiotics","volume":"60 Suppl 2","author":"Doron S","year":"2015","unstructured":"Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015, 60 Suppl 2:S129-34. 10.1093\/cid\/civ085","journal-title":"Clin Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12032","article-title":"Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation","volume":"36","author":"Hasselblatt P","year":"2012","unstructured":"Hasselblatt P, Drognitz K, Potthoff K, et al.. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther. 2012, 36:725-35. 10.1111\/apt.12032","journal-title":"Aliment Pharmacol Ther"},{"key":"ref30","article-title":"Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis","volume":"10","author":"Ha C","year":"2014","unstructured":"Ha C, Kornbluth A. Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2014, 10:793-800.","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/255731-novel-pharmaceuticals-and-therapeutics-for-tumor-necrosis-factor-alpha-resistant-crohns-disease-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T15:19:41Z","timestamp":1721920781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/255731-novel-pharmaceuticals-and-therapeutics-for-tumor-necrosis-factor-alpha-resistant-crohns-disease-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.65357","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,25]]}}}